FDA Authorizes First Oral COVID-19 Post-Exposure Prevention Medication

The U.S. FDA has granted approval for Xocova (ensitrelvir), an oral antiviral medication, for use as post-exposure prophylaxis against COVID-19. This marks a significant development as it is the first oral treatment available to prevent the virus after exposure. The approval applies to adults and adolescents aged 12 and older, filling a crucial gap in current COVID-19 prevention strategies.